Haejeong Heo
Overview
Explore the profile of Haejeong Heo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Park S, Haam K, Heo H, Kim D, Kim M, Jung H, et al.
Mol Oncol
. 2024 Nov;
PMID: 39540457
Anaplastic lymphoma kinase (ALK; also known as ALK tyrosine kinase receptor) inhibitors (ALKi) are effective in treating lung cancer patients with chromosomal rearrangement of ALK. However, continuous treatment with ALKis...
2.
Heo H, Kim H, Haam K, Sohn H, Shin Y, Go H, et al.
Mol Cells
. 2023 Mar;
46(5):298-308.
PMID: 36896596
Gastric cancer (GC) is a complex disease influenced by multiple genetic and epigenetic factors. Chronic inflammation caused by infection and dietary risk factors can result in the accumulation of aberrant...
3.
Kim H, Park J, Yoon B, Haam K, Heo H, Kim J, et al.
Cancers (Basel)
. 2022 Dec;
14(24).
PMID: 36551669
The loss-of-function variants are thought to be associated with inflammation in the stomach. We here aimed to evaluate the extent and role of methylation at the promoter in inflammation and...
4.
Heo H, Kim J, Lim H, Kim J, Kim M, Koh J, et al.
Exp Mol Med
. 2022 Aug;
54(8):1236-1249.
PMID: 35999456
Acquired resistance to inhibitors of anaplastic lymphoma kinase (ALK) is a major clinical challenge for ALK fusion-positive non-small-cell lung cancer (NSCLC). In the absence of secondary ALK mutations, epigenetic reprogramming...
5.
Kim H, Yoon B, Oh C, Lee J, Lee K, Song H, et al.
Diabetes
. 2019 Dec;
69(3):355-368.
PMID: 31848151
Loss of functional β-cell mass is an essential feature of type 2 diabetes, and maintaining mature β-cell identity is important for preserving a functional β-cell mass. However, it is unclear...
6.
Kim S, Kim H, Park J, Heo H, Kim S, Lee S, et al.
Gastric Cancer
. 2019 Nov;
23(3):473-482.
PMID: 31773340
Background: Although recent advances in high-throughput technology have provided many insights into gastric cancer (GC), few reliable biomarkers for diffuse-type GC have been identified. Here, we aim to identify a...
7.
Kim S, Kim S, Kim C, Roh S, Ha Y, Lee J, et al.
Exp Mol Med
. 2019 Oct;
51(10):1-12.
PMID: 31578316
Approximately half of colorectal cancer (CRC) patients experience disease recurrence and metastasis, and these individuals frequently fail to respond to treatment due to their clinical and biological diversity. Here, we...
8.
Cho S, Kim K, Kim J, Kwon O, Go Y, Kang N, et al.
Biomaterials
. 2018 Jul;
180:12-23.
PMID: 30014963
Human and mouse embryonic stem cells (ESCs) differ in terms of their pluripotency status, i.e., naïve vs. primed. This affects various biological properties and leads to several technical hurdles for...
9.
Lim B, Kim H, Heo H, Huh N, Baek S, Kim J, et al.
Cancer Med
. 2018 Jun;
7(7):3411-3424.
PMID: 29862663
Epigenetic dysregulation is a major driver of tumorigenesis. To identify tumor-suppressive microRNAs repressed by DNA methylation in gastric cancer (GC), we analyzed the genome-wide DNA methylation and microRNA expression profiles...